GLUE
Monte Rosa Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | -4 | 40.74M | $985.15M | +4 | −8 |
| Q1 2026 | 84 | +11 | 37.29M | $613.27M | +14 | −3 |
| Q4 2025 | 73 | -1 | 26.21M | $411.01M | +1 | −2 |
| Q3 2025 | 18 | +2 | 20.02M | $148.32M | +2 | n/a |
| Q2 2025 | 13 | +1 | 20.51M | $92.50M | +1 | n/a |
| Q1 2025 | 9 | -3 | 9.96M | $46.20M | +1 | −4 |
| Q4 2024 | 12 | +2 | 11.82M | $82.01M | +2 | n/a |
| Q3 2024 | 9 | +2 | 9.48M | $50.23M | +2 | n/a |
| Q2 2024 | 7 | n/a | 8.29M | $30.99M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 5.98M | n/a | $22.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Citadel Advisors ✦ | 995.94K | n/a | $3.72M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 847.44K | n/a | $3.17M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Renaissance Technologies ✦ | 254.71K | n/a | $952,630 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 166.67K | n/a | $623,350 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 23.42K | n/a | $87,598 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 20.93K | n/a | $78,271 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 188 holders, 86.88M shares, $1.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 13 sh · $137
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.9% of class · View original SEC filing ↗